Scientists have unveiled high-resolution crystal structures of the human cannabinoid receptor CB1 bound to two distinct agonists. This advancement elucidates the receptor's activation mechanisms, which are critical for understanding how Δ9-tetrahydrocannabinol, the psychoactive component of cannabis, exerts its effects. These structural insights pave the way for drug development targeting CB1 with improved specificity and fewer side effects, impacting therapeutics for pain, appetite, and mood disorders.